Bruker Introduces maXis HD Ultra-High Resolution QTOF
At the 12th Human Proteome Organization World Congress (www.hupo.org/2013), Bruker completed its series of High-Definition (HD) QTOF systems introductions with the launch of its new flagship maXis HD ultra-high resolution (UHR) QTOF mass spectrometer. With its best-in-class full sensitivity resolution (FSR) greater than 75,000, the new maXis HD is ideally suited for top-down proteomic analyses and the characterisation of biopharmaceuticals.
The novel maXis HD features a new High-Definition Collision (HDC) cell which enables its record-breaking full sensitivity mass resolution, as well as accurate mass capabilities well beyond all competing QTOF As a result of its extreme sensitivity broad mass-transfer ion optics and the fastest available 50 Gbit/s sampling technology, a dynamic range of five orders of magnitude is achieved in one second of LC time. High dynamic range at high speed is a prerequisite for high-resolution detection of low-abundance compounds in sharp UHPLC peaks and permits direct identification and quantitation without re-runs.
The maXis HD offers break-through analytical performance for applications in top-down proteomics and in biopharmaceutical compound analysis, and the instrument excels in the analysis of intact proteins and antibodies. For antibody subunits, it can provide unprecedented insight into antibody structures via its ultra-high resolution at high mass with baseline discrimination of isotope envelopes at excellent mass accuracy.
The maXis HD also delivers a new confidence level in the fast, high-resolution, accurate mass screening, identification and quantification of small molecules. The novel HDC cell and HD detection technology translate directly into enhanced dynamic range and extreme sensitivity down to very low masses at UHPLC speed, a precondition for one-shot plug and play acquisitions in multi-target applications. The recording-breaking full sensitivity resolution in combination with the Bruker proprietary, real-time SmartFormula 3D software makes the maXis HD the tool of choice for true unknown screening and the ab initio determination of elemental composition at UHPLC speed and throughput.
Dr Michael Schubert, President of the Bruker Daltonics Life-Science & Clinical Division, stated: “With these performance features we believe that the new maXis HD delivers the fastest time-to-success for customers across a broad applications portfolio, covering small molecule identification and characterisation; food, forensic and environmental screening; metabolomics; as well as top-down proteomics and antibody analysis."
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance